Senestech (NASDAQ:SNES – Get Free Report) and Rockwell Medical (NASDAQ:RMTI – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Senestech and Rockwell Medical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senestech | 1 | 1 | 0 | 1 | 2.33 |
| Rockwell Medical | 1 | 0 | 1 | 0 | 2.00 |
Rockwell Medical has a consensus target price of $2.50, suggesting a potential upside of 150.00%. Given Rockwell Medical’s higher possible upside, analysts plainly believe Rockwell Medical is more favorable than Senestech.
Risk & Volatility
Insider and Institutional Ownership
5.2% of Senestech shares are owned by institutional investors. Comparatively, 23.3% of Rockwell Medical shares are owned by institutional investors. 5.3% of Senestech shares are owned by company insiders. Comparatively, 3.6% of Rockwell Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Senestech and Rockwell Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senestech | -253.54% | -98.35% | -73.17% |
| Rockwell Medical | -7.30% | -16.77% | -9.88% |
Earnings and Valuation
This table compares Senestech and Rockwell Medical”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Senestech | $1.86 million | 5.00 | -$6.18 million | ($3.65) | -0.49 |
| Rockwell Medical | $101.49 million | 0.39 | -$480,000.00 | ($0.16) | -6.25 |
Rockwell Medical has higher revenue and earnings than Senestech. Rockwell Medical is trading at a lower price-to-earnings ratio than Senestech, indicating that it is currently the more affordable of the two stocks.
Summary
Rockwell Medical beats Senestech on 10 of the 15 factors compared between the two stocks.
About Senestech
SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.
About Rockwell Medical
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Receive News & Ratings for Senestech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senestech and related companies with MarketBeat.com's FREE daily email newsletter.
